Thymic carcinoma has been recognized as an entity that is different. Treatment and Prognosis of Thymic Carcinoma. A Retrospective Analysis of 40 Cases
|
|
- Noreen Parsons
- 5 years ago
- Views:
Transcription
1 3115 Treatment and Prognosis of Thymic Carcinoma A Retrospective Analysis of 40 Cases Kazuhiko Ogawa, M.D. 1 Takafumi Toita, M.D. 1 Takashi Uno, M.D. 2 Nobukazu Fuwa, M.D. 3 Yasumasa Kakinohana, Ph.D. 1 Minoru Kamata, M.D. 3 Kageharu Koja, M.D. 4 Takao Kinjo, M.D. 5 Genki Adachi, M.D. 1 Sadayuki Murayama, M.D. 1 1 Department of Radiology, University of the 2 Department of Radiology, Chiba University, School of Medicine, Chiba, Japan. 3 Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. 4 Second Department of Surgery, University of the 5 Department of Pathology, University of the BACKGROUND. Thymic carcinomas are rare neoplasms, and information regarding the results of treatment and possible prognostic factors in patients with these tumors is limited. METHODS. The records of 40 patients with histologically confirmed thymic carcinoma who were treated between 1984 and 1998 were reviewed. Twenty-seven patients were treated with surgical resection followed by radiotherapy with or without chemotherapy, and the remaining 13 patients were treated with radiotherapy with or without chemotherapy. The median follow-up time for the 13 surviving patients was 87 months (range, months). RESULTS. The 5-year and 10-year actuarial overall survival rates in all patients were 38% and 28%, respectively. On univariate analysis, complete resection, Karnofsky performance status (KPS), histology, and Masaoka stage at the time of diagnosis were found to have a significant impact on overall survival, whereas on multivariate analysis, complete resection, KPS, and histology were found to be significant prognostic factors. With regard to the degree of resection, 12 of 16 patients (75%) treated with complete resection were alive and free of disease at the time of last follow-up whereas 1 of 24 patients (4%) treated with incomplete resection or biopsy still was alive. Among 12 surviving patients treated with complete resection, 8 with resectable tumors at the time of presentation all had low-grade histology (squamous cell carcinoma) and were treated successfully with complete resection and postoperative radiotherapy with or without adjuvant chemotherapy. The remaining four patients with unresectable tumors at the time of presentation were treated successfully with neoadjuvant chemotherapy, complete resection, and postoperative radiotherapy. CONCLUSIONS. The results of the current study indicate that multimodal treatment, especially complete resection and postoperative radiotherapy with or without chemotherapy, is a curative therapy for thymic carcinomas. Cancer 2002;94: American Cancer Society. DOI /cncr KEYWORDS: thymoma, thymic carcinoma, radiation therapy, surgery, chemotherapy, multimodality treatments. Address for reprints: Kazuhiko Ogawa, M.D., Department of Radiology, University of the Ryukyus School of Medicine, 207 Uehara, Nishihara-cho, Okinawa, , Japan; Fax: (011) ; kogawa@med.u-ryukyu.ac.jp Received November 26, 2001; accepted January 15, Thymic carcinoma has been recognized as an entity that is different from thymoma, because of its obvious cytologic atypia, more invasive nature, and malignant behavior. 1 4 These tumors usually are advanced and have a higher recurrence rate and worse survival compared with the majority of thymomas. 5 The histologic classification of thymic carcinoma was proposed by Levine and Rosai 6 and revised by Suster and Rosai. 1 The tumors are classified broadly as being of low-grade and high-grade histology. Low-grade histology includes squamous cell carcinoma, mucoepidermoid carcinoma, and basaloid carcinoma. Those tumors with high-grade histology include lympho American Cancer Society
2 3116 CANCER June 15, 2002 / Volume 94 / Number 12 epithelioma-like carcinoma, small cell carcinoma, undifferentiated carcinoma, sarcomatoid carcinoma, and clear cell carcinoma. 1,7,8 Although surgical resection has been the first line of treatment of thymic carcinoma, radiotherapy and/or chemotherapy also have been utilized in cases that are unresectable. 1,7 9 However, information regarding treatment modalities and long-term prognosis has been limited by the rarity of this entity. In the current study, we reviewed a retrospective series of 40 patients with thymic carcinoma and indicated possible curative treatments in patients with these tumors. TABLE 1 Treatment Modalities in All 40 Patients with Thymic Carcinoma Treatment modalities No. of patients C SR RT 6 4 SR RT C 4 2 SR RT C RT 10 RT 3 Total CR: complete resection; C: chemotherapy; SR: surgical resection; RT: radiotherapy. No. of patients treated with CR MATERIALS AND METHODS A retrospective review of medical records identified 40 consecutive patients with histologically confirmed thymic carcinoma who were treated at the Department of Radiology, University of the Ryukyus Hospital, Chiba University Hospital, Aichi Cancer Center, and affiliated hospitals between The ages of the patients ranged from years (median, 55 years); 29 patients were male and 11 were female. At the time of presentation, an asymptomatic mass was present on the chest radiograph in 16 patients, symptoms of mediastinal compression (such as chest pain and dyspnea) were present in 16 patients, superior vena cava syndromes were present in 4 patients, hoarseness was present in 2 patients, and bloody sputum was present in 2 patients. None of these patients had concomitant paraneoplastic syndromes such as myasthenia gravis or pure red cell aplasia. All pathologic specimens and surgical reports were reviewed by a coauthor pathologist (K.T.). The criteria for the diagnosis of thymic carcinoma were those exhibiting clear-cut cytologic atypia and a set of cytoarchitectural features no longer specific to the thymus in the absence of a primary tumor at sites other than the anterior mediastinum, either at the time of presentation or at follow-up. The tumors were classified into squamous cell carcinoma (n 29 patients), small cell carcinoma (n 4 patients), undifferentiated carcinoma (n 4 patients), and lymphoepithelioma-like carcinoma (n 3 patients). Therefore, 29 patients had low-grade histology (squamous cell carcinoma) and the remaining 11 patients had high-grade histology. Pretreatment evaluation of the tumor was done by physical examination, chest radiography, chest computed tomography (CT) scan, abdominal CT scan, brain CT scan, abdominal ultrasonography, and bone scan. Clinical staging at the time of diagnosis was based on the criteria described by Masaoka et al. 10 The criteria used in this study are as follows. Stage I indicated macroscopically completely encapsulated disease and no microscopic capsular invasion. Stage II indicated 1) macroscopic invasion into surrounding fatty tissue or mediastinal pleura and/or 2) microscopic invasion into the capsule. Stage III indicated macroscopic invasion into neighboring organs (pericardium, great vessels, or lung). Stage IVA indicated pleural and/or pericardial dissemination of thymoma and Stage IVB indicated lymphogenous or hematogenous metastases. Seven patients had Stage II disease, 18 patients had Stage III disease, and 15 patients had Stage IV disease. Twenty-seven patients were treated with surgical resection (total resection in 16 patients and incomplete resection in 11 patients) followed by radiotherapy with or without chemotherapy. Of these 27 patients, 6 received neoadjuvant chemotherapy and 4 received adjuvant chemotherapy. The remaining 13 patients were treated with radiotherapy with or without chemotherapy (3 patients were treated with radiotherapy alone). The various treatment modalities are listed in Table 1. Radiotherapy was administered with a 60 Cobalt ( 60 CO) teletherapy unit or a 6-megavolt (MV) or 10-MV linear accelerator ( 60 Co teletherapy unit was used in 6 patients). Patients were treated with involved fields that covered the primary tumor or tumor bed with margins of approximately 1 2 cm. Patients were treated with anteroposterior opposed fields with the spinal cord dose limited to 45 grays (Gy) in all cases. Two anterior wedged portals or off-cord oblique opposed portals were used to boost the anterior mediastinum to higher doses. The total dose to the primary tumor or the tumor bed in all patients was Gy (median, 50 Gy). For 16 patients treated with complete resection, a total dose of Gy (median, 50 Gy) was administered. Daily fraction sizes of Gy, 5 days per week, were used. Twenty patients (50%) received various regimens of systemic chemotherapy during the initial treatment. Sixteen of 20 patients received a combination of cisplatin and the most used regimen was a combination of cisplatin,
3 Thymic Carcinoma/Ogawa et al FIGURE 1. Actuarial overall survival rate in all 40 patients with thymic carcinoma. doxorubicin, vincristine, and cyclophosphamide (ADOC). 11 To assess the prognostic factors for overall survival, the data were analyzed with respect to age, gender, Karnofsky performance status (KPS), histology, Masaoka stage at the time of diagnosis, complete resection, total dose, and use of chemotherapy. The median follow-up time of the 13 surviving patients was 87 months (range, months), and no patients were lost to follow-up. Overall survival rates were calculated actuarially according to the Kaplan Meier method 12 and were measured from the day of diagnosis. Differences between groups were estimated using the generalized Wilcoxon test. 13 Multivariate analysis was performed using the Cox regression model. 14 A probability level of 0.05 was chosen for statistical significance. Statistical analysis was performed using the SPSS software package (Version 6.1; SPSS, Inc., Chicago, IL). RESULTS Recurrences were observed in 27 of 40 patients (68%). Local recurrence was the most frequent site of first recurrence (15 patients) and 8 patients had distant metastases at the time of first recurrence (4 patients in the lung, 2 patients in the bone, 1 patient each in the lung and liver, and 1 patient in the lung and bone). Two patients developed recurrence at both the primary lesion and distant metastases (one in the lung and one in the bone) and the two patients had recurrence at both the primary lesion and extrathoracic lymph nodes. None of the 16 patients who were treated with complete resection followed by radiotherapy developed local (in-field) recurrence. Twenty-seven of 40 patients (68%) died during the period of this analysis, all of whom died of thymic carcinoma. The 5-year and 10-year actuarial overall survival rates in all patients were 38% and 28%, respectively (Fig. 1). The median survival time in those patients with low-grade histology was 29 months, and was 11 months in those patients with high-grade histology. On univariate analysis, complete resection, KPS, histology, and Masaoka stage at the time of diagnosis were found to have a significant impact on overall survival (Table 2). On multivariate analysis, complete resection, KPS, and histology were found to be significant prognostic factors (Table 3). Therefore, the results of these analyses indicated that complete resection, a KPS 70%, and low-grade histology were favorable prognostic factors for overall survival. Of those patients treated with complete resection, 12 of 16 patients (75%) were alive and free of disease at the time of last follow-up (follow-up range, months). Conversely, of the 24 patients treated with incomplete resection or biopsy, only 1 patient (4%) with low-grade histology who was treated with incomplete resection, postoperative radiotherapy, and adjuvant chemotherapy was alive with a follow-up of 57 months. Among 12 surviving patients treated with complete resection, 8 with resectable tumors at the time of presentation (Masaoka Stage II in 6 patients and Stage III in 2 patients) had low-grade histology and were treated successfully with complete resection and postoperative radiotherapy with or without adjuvant chemotherapy (follow-up range, months). The remaining 4 patients with unresectable tumors at the time of presentation (Masaoka Stage III) were treated successfully with neoadjuvant chemo-
4 3118 CANCER June 15, 2002 / Volume 94 / Number 12 TABLE 2 Univariate Analysis of Various Potential Prognostic Factors for Survival in Patients with Thymic Carcinoma Variable No. of cases OS 5-year rate (%) P value Complete resection Yes No KPS (%) Histology Low grade High grade Masaoka stage a II 7 86 III and IV Total dose of RT (Gy) Age (yrs) Gender Male Female Use of chemotherapy Yes No OS: overall survival; KPS: Karnofsky performance status; RT: radiotherapy; Gy: grays. a At the time of diagnosis. TABLE 3 Multivariate Analysis of Various Potential Prognostic Factors for Survival in Patients with Thymic Carcinoma Variable P value RR (95% CI) Complete resection ( ) KPS ( ) Histology ( ) Masaoka stage a 0.41 Total dose of RT 0.79 Age 0.24 Gender 0.13 Use of chemotherapy 0.32 RR: relative risk; 95% CI: 95% confidence interval; KPS: Karnofsky performance status; RT: radiotherapy. a At the time of diagnosis. therapy, complete resection, and postoperative radiotherapy (follow-up range, months). The histology of these four patients was squamous cell carcinoma in two patients, small cell carcinoma in one patient, and undifferentiated carcinoma in one patient. The chemotherapy regimens used for these four patients were the ADOC regimen in three patients and a cisplatin and etoposide regimen in one patient. DISCUSSION There is a general consensus that surgery is the treatment of first choice for thymomas, and the extent of surgery is a significant factor for survival. Therefore, many authors have recommended complete resection whenever possible. 15,16 Conversely, the efficacy of complete resection for thymic carcinoma remains unclear. Some reports have failed to show an improved survival in patients who undergo complete resection compared with those undergoing incomplete resection. 5,8 Others have indicated that the most important factor related to the prognosis of patients was the resectability of the tumor at surgery. 2,4 In the current study, the extent of surgery also was found to be a strong predictor of survival in patients with thymic carcinoma. Twelve of 16 patients (75%) who were treated with complete resection were alive and free of disease at the time of last follow-up, whereas only 1 of 24 patients (4%) treated with incomplete resection or biopsy was still alive. These results indicate that complete resection also is recommended in patients with thymic carcinoma, as well as those with thymoma. The histologic classification of thymic carcinoma has been important because of its prognostic significance. 1,3 Tumors in the high-grade histology group are characterized by an aggressive clinical course and a high incidence of local recurrence and distant metastases. Conversely, tumors in the low-grade histology group are characterized by a relatively favorable clinical course and a low incidence of local recurrence and distant metastases. 1 3,17 In the current study, the median survival time in patients with low-grade histology was 29 months, but was only 11 months in those patients with high-grade histology. Several reports also indicated median survivals of months in patients with low-grade histology compared with median survivals of months in patients with highgrade histology. 8,18 The reasons for such a good prognosis with low-grade tumors presumably are the high complete resection rate, the radiosensitivity of the tumor, and the tumor s indolent clinical course. 2,18 In the current study, of the 12 surviving patients treated with complete resection, 8 with resectable tumors at the time of presentation (Masaoka Stage II disease in 6 patients and Stage III disease in 2 patients) had lowgrade histology and were treated successfully with complete resection and postoperative radiotherapy with or without adjuvant chemotherapy. These results indicate that surgical resection and postoperative radiotherapy with or without adjuvant chemotherapy are the treatment of choice in patients with resectable thymic carcinoma with a low-grade histology. To our knowledge, a role for radiotherapy in the
5 Thymic Carcinoma/Ogawa et al treatment of thymic carcinoma has not been established; however, several authors have indicated that thymic carcinoma was as highly sensitive to irradiation as thymoma. 2,9 In the current study, no local recurrence was observed in patients treated with complete resection followed by radiotherapy with a median dose of 50 Gy. Postoperative radiotherapy with a total dose of 50 Gy appears to be effective in preventing local recurrence in patients treated with complete resection. Thymic carcinomas usually are invasive or metastatic at the time of diagnosis (Masaoka Stage III and Stage IV) and complete resection occasionally is impossible to achieve. The dismal prognosis of patients with advanced thymic carcinoma has made it necessary to experiment with new treatment modalities. 5,19 Recently, a good response rate to chemotherapy has been reported in the literature 7,20,21 and multimodal strategies have been advocated. 5,8,9,19 Lucchi et al. reported the results of multimodality treatment including neoadjuvant chemotherapy, surgery, and postoperative radiotherapy. 19 Seven patients with Masaoka Stage III tumors responded to neoadjuvant chemotherapy, and surgical resection was complete in four cases. Of these 4 patients, 3 still were alive and free of disease with a follow-up of months. In the current study, 4 patients with unresectable tumors at the time of presentation underwent complete resection with a good response using neoadjuvant chemotherapy, and all 4 patients were alive and free of disease with a follow-up of months. To our knowledge no recommended regimen of chemotherapy has been clearly established, although some authors have advocated a cisplatin- and/or doxorubicinbased combination. 7,9,11,18,20,22 For advanced tumors that appear to be unresectable at the time of presentation, preoperative shrinkage of the thymic carcinoma by means of neoadjuvant chemotherapy may improve the resectability and, therefore, the survival rate. Further prospective studies with a greater number of patients and also with different chemotherapeutic regimens are necessary to validate this treatment modality. REFERENCES 1. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer. 1991;67: Shimosato Y, Kameya T, Nagai K, Suemasu K. Squamous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol. 1977;1: Truong LD, Mody DR, Cagle PT, Jackson-York GL, Schwartz MR, Wheeler TM. Thymic carcinoma. A clinicopathologic study of 13 cases. Am J Surg Pathol. 1990;14: Tsuchiya R, Koga K, Matsuno Y, Mukai K, Shimosato Y. Thymic carcinoma: proposal for pathological TNM and staging. Pathol Int. 1994;44: Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging dose not predict prognosis. J Thorac Cardiovasc Surg. 1998;115: Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol. 1978;9: Weide LG, Ulbright TM, Loehrer PJ Sr., Williams SD. Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer. 1993;71: Hsu CP, Chen CY, Chen CL, et al. Thymic carcinoma. Ten years experience in twenty patients. J Thorac Cardiovasc Surg. 1994;107: Yano T, Hara N, Ichinose Y, Asoh H, Yokoyama H, Ohta M. Treatment and prognosis of primary thymic carcinoma. J Surg Oncol. 1993;52: Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48: Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991;68: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: Gehan E. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika. 1965;52: Cox DR. Regression models and life tables. J R Stat Soc. 1972;34: Graeber GM, Tamim W. Current status of the diagnosis and treatment of thymoma. Semin Thorac Cardiovasc Surg. 2000;12: Ogawa K, Uno T, Toita T, et al. Postoperative radiotherapy for completely resected thymoma: a multiinstitutional retrospective review of 103 patients. Cancer. 2002;94: Hartmann CA, Roth C, Minck C, Niedobitek G. Thymic carcinoma. Report of five cases and review of the literature. J Cancer Res Clin Oncol. 1990;116: Chang HK, Wang CH, Liaw CC, et al. Prognosis of thymic carcinoma: analysis of 16 cases. J Formos Med Assoc. 1992; 91: Lucchi M, Mussi A, Basolo F, Ambrogi MC, Fontanini G, Angeletti CA. The multimodailty treatment of thymic carcinoma. Eur J Cardiothorac Surg. 2001;19: Dy C, Calvo FA, Mindan JP, et al. Undifferentiated epithelialrich invasive malignant thymoma: complete response to cisplatin, vinblastine, and bleomycin therapy. J Clin Oncol. 1988;6: Carlson RW, Dorfman RF, Sikic BI. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Cancer. 1990;66: Loehrer PJ Sr., Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:
The Role of Radiotherapy for Thymic Carcinoma
The Role of Radiotherapy for Thymic Carcinoma Tetsuo Nonaka 1,2, Yoshio Tamaki 1, Keiko Higuchi 1, Hiroyuki Katoh 1, Masumi Nakahashi 1, Hiroyuki Horikoshi 1, Kenro Takahashi 3, Koichi Minato 4, Shiro
More informationTNM classifications have been established for various
Lymphogenous and Hematogenous Metastasis of Thymic Epithelial Tumors Kazuya Kondo, MD, PhD, and Yasumasa Monden, MD, PhD Department of Oncological and Regenerative Surgery, School of Medicine, University
More informationThymic neoplasms are the most common tumors of
Thymic Carcinoma: A Multivariate Analysis of Factors Predictive of Survival in 290 Patients Benny Weksler, MD, Rajeev Dhupar, MD, MBA, Vishal Parikh, BS, Katie S. Nason, MD, MPH, Arjun Pennathur, MD, and
More informationNeoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up
ORIGINAL ARTICLE Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up Marco Lucchi, MD,* Franca Melfi, MD,* Paolo Dini, MD,* Fulvio Basolo, MD,
More informationClinical Usefulness of the WHO Histological Classification of Thymoma
Original Article Clinical Usefulness of the WHO Histological Classification of Thymoma Satoshi Sonobe, MD, 1 Hideaki Miyamoto, MD, 1 Hiroshi Izumi, MD, 2 Bunsei Nobukawa, MD, 2 Toshiro Futagawa, MD, 1
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationOutcome of nonsurgical treatment for locally advanced thymic tumors
Original Article Outcome of nonsurgical treatment for locally advanced thymic tumors Chang-Lu Wang 1, Lan-Ting Gao 1, Chang-Xing Lv 1, Lei Zhu 2, Wen-Tao Fang 3 1 Department of Radiation Oncology, 2 Department
More informationSurgical treatment of thymoma: an 11-year experience with 761 patients
European Journal of Cardio-Thoracic Surgery 49 (2016) 1144 1149 doi:10.1093/ejcts/ezv288 Advance Access publication 30 August 2015 ORIGINAL ARTICLE Cite this article as: Zhao Y, Shi J, Fan L, Hu D, Yang
More informationThymic Tumors. Feiran Lou MD. MS. Kings County Hospital Department of Surgery
Thymic Tumors Feiran Lou MD. MS. Kings County Hospital Department of Surgery Case HPI 53 yo man referred from OSH for anterior mediastinal mass. Initially presented with leg weakness and back pain for
More informationThymic epithelial tumors mainly consist of thymoma,
Therapy for Thymic Epithelial Tumors: A Clinical Study of 1,320 Patients From Japan Kazuya Kondo, MD, PhD, and Yasumasa Monden, MD, PhD Department of Oncological and Regenerative Surgery, School of Medicine,
More informationWHO Histologic Classification is a Prognostic Indicator in Thymoma
WHO Histologic Classification is a Prognostic Indicator in Thymoma Kazuya Kondo, MD, PhD, Kiyoshi Yoshizawa, MD, PhD, Masaru Tsuyuguchi, MD, PhD, Suguru Kimura, MD, PhD, Masayuki Sumitomo, MD, Junji Morita,
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThymoma and Thymic Carcinoma
Thymoma and Thymic Carcinoma Protocol applies to thymic epithelial tumors located in any area of the mediastinum. Procedures Biopsy Resection Protocol revision date: January 2004 No AJCC/UICC staging system
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationTreatment and prognosis of type B2 thymoma
Song et al. World Journal of Surgical Oncology 2014, 12:291 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Treatment and prognosis of type B2 thymoma Zhengbo Song 1,2, Xiangyu Jin 1,2 and Yiping
More informationResection of Thymic Carcinoma in a Patient with Thoracic Aortic Aneurysm
Case Report Resection of Thymic Carcinoma in a Patient with Thoracic Aortic Aneurysm Makoto Nonaka, MD, 1 Mitsutaka Kadokura, MD, 1 Shigeru Yamamoto, MD, 1 Daisuke Kataoka, MD, 1 Atsushi Bito, MD, 1 Mitsuru
More informationPostoperative Radiotherapy for Completely Resected Stage II or III Thymoma
ORIGINAL ARTICLE Postoperative Radiotherapy for Completely Resected Stage II or III Thymoma Ji Hyun Chang, MD,* Hak Jae Kim, MD, PhD,* Hong-Gyun Wu, MD, PhD,* Joo Hyun Kim, MD, PhD, and Young Tae Kim,
More informationInsights into Thymic Epithelial Tumors: Radiation Therapy
Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationARRO Case Thymoma. Jordan Kharofa, MD Elizabeth Gore, MD Medical College of Wisconsin
ARRO Case Thymoma Jordan Kharofa, MD Elizabeth Gore, MD Medical College of Wisconsin History HPI 54 yo male who presented to PCP with complaining subacute shortness of breath and chest pain. Pain increased
More informationThe role of adjuvant chemotherapy following resection of early stage thymoma
Perspective The role of adjuvant chemotherapy following resection of early stage thymoma Masatsugu Hamaji Department of Thoracic Surgery, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto,
More informationProtocol for the Examination of Specimens From Patients With Thymic Tumors
Protocol for the Examination of Specimens From Patients With Thymic Tumors Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual For accreditation
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationInvasive Thymoma: The Role of Mediastinal Irradiation Following Complete or Incomplete Surgical Resection
Invasive Thymoma: The Role of Mediastinal Irradiation Following Complete or Incomplete Surgical Resection By Walter J. Curran, Jr, Michael J. Kornstein, John J. Brooks, and Andrew T. Turrisi III To evaluate
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationIn the 1960s, thymomas were classified into two categories: Staging System of Thymoma MALIGNANCIES OF THE THYMUS. Akira Masaoka, MD, PhD S304
MALIGNANCIES OF THE THYMUS Akira Masaoka, MD, PhD Introduction: Thirty years have gone by since the Masaoka staging system of thymoma was proposed in 1981. Although the Masaoka staging system has been
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationTHYMOMAS AND THYMIC CARCINOMAS: A REVIEW ON PATHOLOGY, PRESENTATION, STAGING, TREATMENT, AND NOVEL SYSTEMIC THERAPIES
THYMOMAS AND THYMIC CARCINOMAS: A REVIEW ON PATHOLOGY, PRESENTATION, STAGING, TREATMENT, AND NOVEL SYSTEMIC THERAPIES Keisuke Miyamoto, 1 *Jared D. Acoba 1,2 1. Internal Medicine Department, University
More informationAdvanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome
Original Article Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome Chun-Yu Lin 1,2, Ying-Jen Chen 1,2, Meng-Heng Hsieh 2,3, Chih-Wei Wang 2,4,
More informationPrognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems
Original Article Prognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems Geun Dong Lee 1, Hyeong Ryul Kim 2, Se Hoon Choi 2, Yong-Hee Kim 2,
More informationDesign: Retrospective, clinicopathologic analysis of our experience and a review of recent literature.
Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors : a clinicopathologic study of 108 patients and literature review CHEST, March,
More informationD pects of the pathophysiology and treatment of thymomas
CURRENT REVIEW Thymoma: Results of 241 Operated Cases Giuliano Maggi, MD, Caterina Casadio, MD, Antonio Cavallo, MD, Roberto Cianci, MD, Massimo Molinatti, MD, and Enrico Ruffini, MD Department of Thoracic
More informationThymomas are tumors of epithelial cell origin arising. Preoperative CT Findings of Thymoma are Correlated with Postoperative Masaoka Clinical Stage
Preoperative CT Findings of Thymoma are Correlated with Postoperative Masaoka Clinical Stage Yan-juan Qu, MS, Guo-bing Liu, MS, He-shui Shi, MS, PhD, Mei-yan Liao, MS, PhD, Gui-fang Yang, MS, PhD, Zhi-xiong
More informationLong-Term Outcome After Multimodality Treatment for Stage III Thymic Tumors
Long-Term Outcome After Multimodality Treatment for Stage III Thymic Tumors Federico Venuta, MD, Erino A. Rendina, MD, Flavia Longo, MD, Tiziano De Giacomo, MD, Marco Anile, MD, Edoardo Mercadante, MD,
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationTreatment and Prognosis of Patients with Intracranial Nongerminomatous Malignant Germ Cell Tumors
369 Treatment and Prognosis of Patients with Intracranial Nongerminomatous Malignant Germ Cell Tumors A Multiinstitutional Retrospective Analysis of 41 Patients Kazuhiko Ogawa, M.D. 1 Takafumi Toita, M.D.
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationThymic epithelial tumors (TETs) are rare neoplasms arising
ORIGINAL ARTICLE Thymoma A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD,* Alexander Marx, MD, Philipp Ströbel, MD, Edwin Bölke, MD,*
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationValidation of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients
Validation of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic Surgery Shanghai Chest Hospital AATS,Seattle, April
More informationProtocol for the Examination of Specimens From Patients With Thymoma and Thymic Carcinoma
Protocol for the Examination of Specimens From Patients With Thymoma and Thymic Carcinoma Protocol applies to thymic epithelial tumors located in any area of the mediastinum. No AJCC/UICC TNM Staging System
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationThymic malignancies have often been poorly understood,
MALIGNANCIES OF THE THYMUS Evaluation and Treatment of Stage I and II Thymoma Frank C. Detterbeck, MD Abstract: Thymomas are relatively uncommon. Nevertheless, an accumulation of studies (mostly retrospective,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationEsophageal cancer is a significant health hazard for
Postoperative Radiotherapy Improved Survival of Poor Prognostic Squamous Cell Carcinoma Esophagus GENERAL THORACIC Junqiang Chen, MD, Ji Zhu, MD, Jianji Pan, MD, Kunshou Zhu, MD, Xiongwei Zheng, MD, Mingqiang
More informationPathology of Mediastinal Tumors
SAMO Meeting Lucerne 2009 Pathology of Mediastinal Tumors Alex Soltermann Most common lesions (adults) Clinical presentation 50% of the patients are asymptomatic, lesion discovered incidentally Symptoms
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationBecause of the sensitivity of thymoma and thymic carcinoma
MALIGNANCIES OF THE THYMUS Clifton D. Fuller, MD,* Emma H. Ramahi, BA,* Noel Aherne, MD, Tony Y. Eng, MD,* and Charles R. Thomas, Jr., MD Abstract: The role of radiotherapy in the treatment of thymoma
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationPrinciples and Practice of Radiation Oncology. 4 th edition. Chapter 45. Mediastinum and Trachea
Principles and Practice of Radiation Oncology 4 th edition Chapter 45 Mediastinum and Trachea Tony Y. Eng 1, Todd J. Scarbrough 2, Charles R. Thomas, Jr. 3 1 Associate Professor 3 Associate Professor and
More informationTHYMIC CARCINOMAS AN UPDATE
THYMIC CARCINOMAS AN UPDATE Mark R. Wick, M.D. University of Virginia Medical Center Charlottesville, VA CARCINOMA OF THE THYMUS General Clinical Features No apparent gender predilection Age range of 35-75
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationDevelopment of an Expert Consensus Target Delineation Atlas for Thymic Cancers: Initial Quantitative Analysis of an Expert Survey.
Development of an Expert Consensus Target Delineation Atlas for Thymic Cancers: Initial Quantitative Analysis of an Expert Survey. Charles R. Thomas, Jr., MD, Jayashree Kalpathy-Cramer, PhD, Jehee Choi,
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationManagement of metastatic malignant thymoma with advanced radiation and chemotherapy techniques: report of a rare case
D Andrea and Reddy World Journal of Surgical Oncology (2015) 13:77 DOI 10.1186/s12957-014-0427-z WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Management of metastatic malignant thymoma with
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationOriginal Article Clinicopathological features of type AB thymoma with liver metastases
Int J Clin Exp Pathol 2014;7(12):8700-8705 www.ijcep.com /ISSN:1936-2625/IJCEP0002983 Original Article Clinicopathological features of type AB thymoma with liver metastases Zhenzheng Wang 1*, Hui Li 2*,
More informationComparison of Stages I II Thymoma Treated by Complete Resection With or Without Adjuvant Radiation
ORIGINAL ARTICLES: Comparison of Stages I II Thymoma Treated by Complete Resection With or Without Adjuvant Radiation Sunil Singhal, MD, Joseph B. Shrager, MD, David I. Rosenthal, MD, Virginia A. LiVolsi,
More informationEvaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival
Ried et al. World Journal of Surgical Oncology (2017) 15:214 DOI 10.1186/s12957-017-1283-4 RESEARCH Open Access Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationStandardized definitions and policies of minimally invasive thymoma resection
Perspective Standardized definitions and policies of minimally invasive thymoma resection Alper Toker 1,2 1 Department of Thoracic Surgery, Istanbul Medical School, Istanbul University, Istanbul, Turkey;
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationMyasthenia Gravis with Thymoma: Analysis of and Postoperative Prognosis for 65 Patients with Thymomatous Myasthenia Gravis
Myasthenia Gravis with Thymoma: Analysis of and Postoperative Prognosis for 65 Patients with Thymomatous Myasthenia Gravis Yasumasa Monden, M.D., Kazuya Nakahara, M.D., Katsumi Kagotani, M.D., Yoshitaka
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationThe Role of Adjuvant Radiation Therapy for Resected Stage III Thymoma: A Population-Based Study
GENERAL THORACIC The Role of Adjuvant Radiation Therapy for Resected Stage III Thymoma: A Population-Based Study Benny Weksler, MD, Manisha Shende, MD, Katie S. Nason, MD, MPH, Angela Gallagher, CRNP,
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationPrognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients
1 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan 2 Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Hospital East,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationIterative Surgical Treatment for Repeated Recurrences After Complete Resection of Thymic Tumors
GENERAL THORACIC Iterative Surgical Treatment for Repeated Recurrences After Complete Resection of Thymic Tumors Alfonso Fiorelli, MD, PhD, Antonio D Andrilli, MD, PhD, Camilla Vanni, MD, Roberto Cascone,
More informationSurgical Treatment of Complex Malignant Anterior Mediastinal Tumors Invading the Superior Vena Cava
Ó 2006 by the Société Internationale de Chirurgie World J Surg (2006) 30: 162 170 Published Online: 20 January 2006 DOI: 10.1007/s00268-005-0009-x Surgical Treatment of Complex Malignant Anterior Mediastinal
More informationCase Presentation HPI. PMHx: HTN, BPH, psychiatric disorder, negative cardiac stress test 4/2010. Allergies: NKDA
Case Presentation HPI 62 year-old male presents with several episodes of anterior chest pain. Full cardiac evaluation was negative for ischemia. CT scan revealed a 4cm anterior mediastinal mass. Pt denies
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationAdrenal glands are a common metastatic site for non small cell lung cancer
Surgical treatment of solitary adrenal metastasis from non small cell lung cancer Olaf Mercier, MD, Elie Fadel, MD, PhD, Marc de Perrot, MD, Sacha Mussot, MD, Franco Stella, MD, Alain Chapelier, MD, PhD,
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationViable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection. Can We Predict Patients at Risk of Disease Progression?
2700 Viable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection Can We Predict Patients at Risk of Disease Progression? Philippe E. Spiess, MD 1 Nizar M. Tannir, MD 2 Shi-Ming Tu,
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationsarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.
1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationHepatic Resection of Metastatic Testicular Carcinoma: A Further Update
Annals of Surgical Oncology, 6(7):640 644 Published by Lippincott Williams & Wilkins 1999 The Society of Surgical Oncology, Inc. Hepatic Resection of Metastatic Testicular Carcinoma: A Further Update Tara
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationBecause of the indolent course and sporadic occurrence
Thymic Tumors Frank C. Detterbeck, MD, and Alden M. Parsons, MD Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Thymic tumors include thymic carcinoma, which
More information